Vertex Pharmaceuticals Incorporated — FY2010 Form 10-K
Reporting period: Year ended December 31, 2010; filed February 17, 2011. The filing also reports fourth-quarter results. Vertex was a development-stage biopharmaceutical company preparing its lead candidate, telaprevir, for potential launch; it reported no product sales in 2010.
Financial performance and liquidity
| Metric | FY2010 | FY2009 |
|---|---|---|
| Total revenue | $143.4 million | $101.9 million |
| Operating expenses | $839.4 million | $715.9 million |
| Operating loss | $696.1 million | $614.0 million |
| Net loss | $754.6 million | $642.2 million |
| Basic and diluted loss per share | $3.77 | $3.71 |
| Cash, cash equivalents and marketable securities at year-end | $1.031 billion | $1.285 billion |
| Cash used in operating activities | $635.4 million | $427.6 million |
- Revenue rose 41%, chiefly as Mitsubishi Tanabe collaboration revenue increased, including deferred upfront-payment recognition and manufacturing services. Collaboration revenue was $113.1 million; royalty revenue was $30.2 million.
- Operating costs rose 17%. Research and development expense increased 16% to $637.4 million, including $65.9 million of commercial-supply investment. Sales, general and administrative expense rose 44% to $187.8 million as Vertex built its commercial organization.
- Calculated from reported figures, operating margin was approximately negative 485% in 2010, versus negative 602% in 2009; net margin was approximately negative 526% versus negative 630%. These figures reflect large R&D and launch-preparation costs, not established product economics.
- Operating cash outflow increased by $207.9 million year over year. Investing activities provided $7.3 million net, while financing activities provided $425.1 million, including $391.6 million net proceeds from issuing $400 million of 3.35% convertible notes.
- Year-end current assets were $1.057 billion and current liabilities $474.8 million. The company reported $243.2 million of cash and cash equivalents and $788.2 million of current marketable securities.
- Debt included $155 million face value of secured notes due in 2012 and $400 million of convertible notes due in 2015. The 2015 notes bear 3.35% interest and are convertible at approximately $48.83 per share. A $100 million revolving credit facility was arranged in January 2011; the filing does not report a draw.
- Fourth-quarter 2010 revenue was $65.5 million and net loss was $180.4 million, compared with fourth-quarter 2009 revenue of $33.9 million and net loss of $158.6 million.
Material changes and notable items
- Net loss widened 18% year over year despite higher revenue, as operating costs and non-operating losses grew. R&D and commercial launch spending were the principal operating cost drivers.
- Revenue composition shifted: Mitsubishi Tanabe represented 57% of 2010 total revenue and Janssen 21%. Janssen revenue fell to $30.8 million from $54.6 million, while Mitsubishi Tanabe revenue rose to $81.9 million from $18.7 million.
- The company recorded $56.3 million of expenses related to September 2009 financing transactions, primarily non-cash derivative fair-value changes and note discount amortization; this was up from $5.3 million in 2009. It also recorded $41.2 million as the change in derivative fair value in the income statement.
- Operating cash and marketable securities declined $253.5 million during 2010, notwithstanding the convertible-note issuance. Stockholders’ equity fell to $504.0 million from $1.096 billion, while shares outstanding increased to 203.5 million from 200.0 million.
- Vertex expensed all telaprevir commercial-supply costs in 2010, totaling $63 million, and expected to begin capitalizing qualifying inventory in 2011. This accounting transition could affect reported R&D expense and cost of revenue.
- The filing reported no material legal proceedings or material accrued contingent liabilities. Ernst & Young issued unqualified opinions on the financial statements and internal control over financial reporting.
Business, outlook, risks and management commentary
- Telaprevir: Vertex submitted its U.S. NDA in November 2010. The FDA granted priority review in January 2011, with a target review date of May 23, 2011. Management expected a potential U.S. launch in mid-2011 if approved. Canadian and European launches were also targeted for the second half of 2011, subject to approval; Janssen handles commercialization outside North America and the Far East.
- Clinical trial results supported the application: in ADVANCE, SVR rates were 75% for the 12-week telaprevir regimen and 69% for the 8-week regimen, versus 44% for control. In REALIZE, pooled telaprevir-arm SVR was 65% overall, including 31% among prior null responders. These results do not guarantee regulatory approval or commercial success.
- VX-770 for cystic fibrosis was in Phase 3 registration trials. Vertex anticipated key data in 2011 and said it could submit U.S. and European applications in the second half of 2011 if results supported filing. VX-809, VX-222, VX-509 and VX-765 remained earlier-stage programs.
- Management expected current cash, cash equivalents and marketable securities to fund operations for at least 12 months. If telaprevir met expectations for approval and sales, Vertex believed it could become cash-flow positive during 2012. These expectations were conditional; the company had incurred losses every year since inception and cautioned that profitability was not assured.
- Key risks include FDA delay or rejection; competition from Merck’s boceprevir on a similar review timeline; uncertain uptake, pricing, reimbursement and patient diagnosis rates; reliance on collaborators and third-party manufacturers; clinical-development failure; and substantial ongoing spending. The $100 million credit facility includes a $400 million minimum domestic liquidity covenant and net-loss covenant, and borrowing is subject to conditions.
- Other exposures include $518.7 million of ViroChem in-process R&D intangible assets, principally associated with VX-222 and VX-759, which could be impaired if development prospects deteriorate; $29.6 million of lease restructuring liability; and substantial facility lease commitments. A proposed Boston facility was only at letter-of-intent stage and was not a binding lease.
Important facts for investors to verify
- Whether telaprevir received FDA approval on the stated timetable, what labeling and safety requirements applied, and whether a U.S. launch generated the expected sales.
- Whether competing HCV therapies, reimbursement decisions, treatment duration, side effects and commercial execution affected telaprevir uptake and pricing.
- VX-770 Phase 3 results and any subsequent filings, approvals, launch plans or additional clinical requirements.
- Cash burn, cash and marketable-securities balance, credit-facility availability and compliance with its liquidity and loss covenants.
- Repayment or milestone-linked redemption of the 2012 notes, interest and conversion exposure on the 2015 notes, and potential dilution from convertible debt and equity awards.
- Any impairment indicators for ViroChem-related intangible assets, and changes in derivative valuations, restructuring liabilities or inventory capitalization assumptions.